Mazdutide vs. Semaglutide: Phase 3 Trial Design for Diabetes and Obesity

Type 2 diabetes and obesity are global health crises, often co-occurring and significantly increasing the risk of cardiovascular disease, kidney disease, and other complications. Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide have revolutionized treatment by improving glycemic control and promoting weight loss. However, there's a continuous need for novel therapies with potentially superior efficacy or different safety profiles. This study details the rationale, design, and baseline characteristics of a large Phase 3 trial directly comparing a novel dual GLP-1/glucagon receptor agonist, mazdutide, against semaglutide for these conditions.

The DREAMS-3 trial successfully recruited a large cohort of patients with well-matched baseline characteristics, ensuring a robust comparison between treatment arms. At baseline, the enrolled participants had an average HbA1c of 8.1% (±0.8%), indicating poorly controlled type 2 diabetes, and an average body mass index (BMI) of 33.5 kg/m² (±3.2 kg/m²), consistent with obesity. The mean baseline body weight was approximately 95.2 kg (±12.5 kg). The study design ensures that the treatment groups showed no statistically significant differences in key demographic or metabolic parameters at the start of the study (p>0.05 for all baseline comparisons). The trial design represents a significant step forward by directly comparing a novel dual GLP-1/glucagon agonist, Mazdutide, against the established GLP-1 agonist, Semaglutide, in a large, well-characterized patient population. This design allows for a head-to-head assessment of efficacy and safety, with the trial powered to detect clinically meaningful differences in HbA1c and body weight reductions.